VJHemOnc is committed to improving our service to you

ASH 2019 | QUAZAR AML-001: a new standard for AML maintenance therapy

VJHemOnc is committed to improving our service to you

Andrew Wei

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the primary results of QUAZAR AML-001 (NCT01757535), a phase III international, randomized, double-blind, placebo-controlled study evaluating CC-486 (an oral formulation of azacitidine) as a maintenance therapy in older patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy. Studies performed demonstrated that CC-486 has a manageable safety profile and represents a new therapeutic standard for patients with AML in remission. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter